The potential role of appetite in predicting weight changes during treatment with olanzapine

Michael Case, Tamas Treuer, Jamie Karagianis, Vicki Poole Hoffmann, Michael Case, Tamas Treuer, Jamie Karagianis, Vicki Poole Hoffmann

Abstract

Background: Clinically significant weight gain has been reported during treatment with atypical antipsychotics. It has been suggested that weight changes in patients treated with olanzapine may be associated with increased appetite.

Methods: Data were used from adult patients for whom both appetite and weight data were available from 4 prospective, 12- to 24-week clinical trials. Patients' appetites were assessed with Eating Behavior Assessment (EBA, Study 1), Platypus Appetite Rating Scale (PARS, Study 2), Eating Inventory (EI, Study 3), Food Craving Inventory (FCI, Study 3), and Eating Attitude Scale (EAS, Study 4).

Results: In Studies 1 (EBA) and 4 (EAS), patients who reported overall score increases on appetite scales, indicating an increase in appetite, experienced the greatest overall weight gains. However, in Studies 2 (PARS) and 3 (EI, FCI), patients who reported overall score increases on appetite scales did not experience greater weight changes than patients not reporting score increases. Early weight changes (2-4 weeks) were more positively correlated with overall weight changes than early or overall score changes on any utilized appetite assessment scale. No additional information was gained by adding early appetite change to early weight change in correlation to overall weight change.

Conclusions: Early weight changes may be a more useful predictor for long-term weight changes than early score changes on appetite assessment scales.

Clinical trials registration: This report represents secondary analyses of 4 clinical studies. Studies 1, 2, and 3 were registered at https://ichgcp.net/clinical-trials-registry/NCT00190749" title="See in ClinicalTrials.gov">NCT00190749, NCT00303602, and NCT00401973, respectively. Study 4 predates the registration requirements for observational studies that are not classified as category 1 observational studies.

Figures

Figure 1
Figure 1
Study 1 - A) Relationship of overall EBA item score changes and overall weight changes. B) Relationship of 2-week EBA item score changes and overall weight changes. Abbreviations: EBA = Eating Behavior Assessment; kg = kilogram.
Figure 2
Figure 2
Study 4 - A) Relationship of overall EAS item score changes and overall weight changes. B) Relationship of 4-week EAS item score changes and overall weight changes. Abbreviations: EAS = Eating Assessment Scale; kg = kilogram

References

    1. Matsui-Sakata A, Ohtani H, Sawada Y. Receptor occupancy-based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitus. Drug Metab Pharmacokinet. 2005;20:368–378. doi: 10.2133/dmpk.20.368.
    1. Starrenburg FC, Bogers JP. How can antipsychotics cause Diabetes Mellitus? Insights based on receptor-binding profiles, humoral factors and transporter proteins. Eur Psychiatry. 2009;24:164–170. doi: 10.1016/j.eurpsy.2009.01.001.
    1. Palik E, Birkas KD, Faludi G, Karadi I, Cseh K. Correlation of serum ghrelin levels with body mass index and carbohydrate metabolism in patients treated with atypical antipsychotics. Diabetes Res Clin Pract. 2005;68(Suppl 1):S60–S64. doi: 10.1016/j.diabres.2005.03.008.
    1. Weston-Green K, Huang XF, Han M, Deng C. The effects of antipsychotics on the density of cannabinoid receptors in the dorsal vagal complex of rats: implications for olanzapine-induced weight gain. Int J Neuropsychopharmacol. 2008;11:827–835. doi: 10.1017/S1461145708008560.
    1. Baptista T, Zarate J, Joober R, Colasante C, Beaulieu S, Paez X, Hernandez L. Drug induced weight gain, an impediment to successful pharmacotherapy: focus on antipsychotics. Curr Drug Targets. 2004;5:279–299. doi: 10.2174/1389450043490514.
    1. Chintoh AF, Mann SW, Lam L, Lam C, Cohn TA, Fletcher PJ, Nobrega JN, Giacca A, Remington G. Insulin resistance and decreased glucose-stimulated insulin secretion after acute olanzapine administration. J Clin Psychopharmacol. 2008;28:494–499. doi: 10.1097/JCP.0b013e318184b4c5.
    1. Sharpe JK, Stedman TJ, Byrne NM, Wishart C, Hills AP. Energy expenditure and physical activity in clozapine use: implications for weight management. Aust N Z J Psychiatry. 2006;40:810–814.
    1. Reynolds GP, Kirk SL. Metabolic side effects of antipsychotic drug treatment - Pharmacological mechanisms. Pharmacol Ther. 2009. in press .
    1. Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P, Jayathilake K, Meltzer HY, Roth BL. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology. 2003;28:519–526. doi: 10.1038/sj.npp.1300027.
    1. Knolle-Veentjer S, Huth V, Ferstl R, Aldenhoff JB, Hinze-Selch D. Delay of gratification and executive performance in individuals with schizophrenia: putative role for eating behavior and body weight regulation. J Psychiatr Res. 2008;42:98–105. doi: 10.1016/j.jpsychires.2006.10.003.
    1. Cserjesi R, Luminet O, Poncelet AS, Lenard L. Altered executive function in obesity. Exploration of the role of affective states on cognitive abilities. Appetite. 2009;52:535–539. doi: 10.1016/j.appet.2009.01.003.
    1. Kluge M, Schuld A, Himmerich H, Dalal M, Schacht A, Wehmeier PM, Hinze-Selch D, Kraus T, Dittmann RW, Pollmacher T. Clozapine and olanzapine are associated with food craving and binge eating: results from a randomized double-blind study. J Clin Psychopharmacol. 2007;27:662–666. doi: 10.1097/jcp.0b013e31815a8872.
    1. Theisen FM, Linden A, Konig IR, Martin M, Remschmidt H, Hebebrand J. Spectrum of binge eating symptomatology in patients treated with clozapine and olanzapine. J Neural Transm. 2003;110:111–121.
    1. Sentissi O, Viala A, Bourdel MC, Kaminski F, Bellisle F, Olie JP, Poirier MF. Impact of antipsychotic treatments on the motivation to eat: preliminary results in 153 schizophrenic patients. Int Clin Psychopharmacol. 2009;24:257–264. doi: 10.1097/YIC.0b013e32832b6bf6.
    1. Stauffer VL, Lipkovich I, Hoffmann VP, Heinloth AN, McGregor HS, Kinon BJ. Predictors and correlates for weight changes in patients co-treated with olanzapine and weight mitigating agents; a post-hoc analysis. BMC Psychiatry. 2009;9:12. doi: 10.1186/1471-244X-9-12.
    1. Hardy T, Henry RR, Forrester TD, Kryzhanovskaya LA, Watson SB, Marks DM, Mudaliar S. Insulin Sensitivity in Patients with Schizophrenia or Schizoaffective Disorder Treated with Olanzapine or Risperidone [abstract] Presented at APA San Francisco. 2007.
    1. Treuer T, Hoffmann VP, Chen AK, Irimia V, Ocampo M, Wang G, Singh P, Holt S. Factors associated with weight gain during olanzapine treatment in patients with schizophrenia or bipolar disorder: results from a six-month prospective, multinational, observational study. World J Biol Psychiatry. 2009;10:729–740. doi: 10.1080/15622970903079507.
    1. Karagianis J, Grossman L, Landry J, Reed VA, de Haan L, Maguire GA, Hoffmann VP, Milev R. A randomized controlled trial of the effect of sublingual orally disintegrating olanzapine versus oral olanzapine on body mass index: the PLATYPUS Study. Schizophr Res. 2009;113:41–48. doi: 10.1016/j.schres.2009.05.024.
    1. Poole Hoffman V, Case M, Jacobson JG. Algorithms Including Amantadine, Metformin and Zonisamide for Mitigation of Weight Gain During Olanzapine Treatment in Outpatients with Schizophrenia [abstract] Presented at APA San Francisco 2007. 2009.
    1. Stunkard AJ, Messick S. The three-factor eating questionnaire to measure dietary restraint, disinhibition and hunger. J Psychosom Res. 1985;29:71–83. doi: 10.1016/0022-3999(85)90010-8.
    1. White MA, Whisenhunt BL, Williamson DA, Greenway FL, Netemeyer RG. Development and validation of the food-craving inventory. Obes Res. 2002;10:107–114. doi: 10.1038/oby.2002.17.
    1. Kinon BJ, Kaiser CJ, Ahmed S, Rotelli MD, Kollack-Walker S. Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders. J Clin Psychopharmacol. 2005;25:255–258. doi: 10.1097/01.jcp.0000161501.65890.22.
    1. Cooper G, Goudie A, Halford J. Acute effects of olanzapine on behavioural expression including the behavioural satiety sequence in female rats. J Psychopharmacol. 2009. in press .
    1. Baptista T, Contreras Q, Teneud L, Albornoz MA, Acosta A, Paez X, de QM, LaCruz A, Hernandez L. Mechanism of the neuroleptic-induced obesity in female rats. Prog Neuropsychopharmacol Biol Psychiatry. 1998;22:187–198. doi: 10.1016/S0278-5846(97)00101-2.
    1. Karagianis J, Hoffmann VP, Arranz B, Treuer T, Maguire GA, de HL, Chawla B. Orally disintegrating olanzapine and potential differences in treatment-emergent weight gain. Hum Psychopharmacol. 2008;23:275–281. doi: 10.1002/hup.933.
    1. Treuer T, Karagianis J, Hoffmann VP. Can increased food intake improve psychosis? A brief review and hypothesis. Curr Mol Pharmacol. 2008;1:270–272. doi: 10.2174/1874467210801030270.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi